Chemistry: molecular biology and microbiology – Spore forming or isolating process
Patent
1991-07-12
1993-04-13
Lacey, David L.
Chemistry: molecular biology and microbiology
Spore forming or isolating process
53038825, 530413, 4351722, 435 7021, C12N 520, C12N 1502, C07K 1528, C07K 320
Patent
active
052022536
ABSTRACT:
A Ca.sup.2+ dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C. The antibody does not bind to Activated Protein C and can be used to inhibit activation of Protein C by thrombin-thrombomodulin. The antibody can be isolated from cell culture or ascites fluid in large quantities by affinity chromatography with mild conditions using the peptide bound to an immobilized substrate. The antibody has a number of specific uses in isolation and characterization of Protein C and as a model for the design of Ca.sup.2+ dependent antibodies for the isolation of other proteins, as a diagnostic, and as a therapeutic to prevent activation of Protein C. The Protein C can be naturally produced or produced by expression of the recombinant gene. Advantages of the antibody in purification of Protein C include the specificity for Protein C and not Activated Protein C, and the unique Ca.sup.2+ -peptide binding specificity which allows the binding site to be protected when it is being immobilized on the chromatographic support. In vivo, the antibody has been demonstrated to inhibit tumor growth. The antibody can also be used to promote clotting in patients having high levels of Factor VIII inhibitors.
REFERENCES:
patent: 4506009 (1985-03-01), Lenhoff et al.
patent: 5147638 (1992-09-01), Esmon et al.
Seligsohn, et al., The New England Journal of Medicine, vol. 310 No. 9, pp. 559-462 (Mar. 1, 1984).
Vukovich, et al., British Journal of Haematalogy 70, pp. 435-440 (1988).
C. T. Esmon, et al., Joint IABS/CSL Symposium on Standarization in Blood Fractionation including Coagulation Factors, Melbourne, Australia, 1986 Develop. biol. Standard, vol. 67, pp. 51-57 (S. Karger, Basel, 1987).
C. T. Esmon, et al., Journ. of Biol. Chem. vol. 264, No. 9 pp. 4743-4746 (Mar. 25, 1989).
C. T. Esmon, Science vol. 235, pp. 1348-1352 (Mar. 13, 1987).
A. K. Ohlin, et al., Journ. of Biol. Chem. vol. 262, No. 28 pp. 13798-13804 (Oct. 5, 1987).
Laurell, et al., FEBS Letters vol. 191, No. 1, pp. 75-81 (Oct. 1985).
Ohlin, et al., Thrombosis and Haemostasis 58(1): 230 (Jul. 1987).
Freyssinet, et al., Thrombosis and Haemostasis 58(1):230 (Jul., 1987).
Suzuki, et al., J. Biochem. 97, 127-138 (1985).
Stearns, et al., Journ. of Biol. Chem., vol. 263, No. 2, pp. 826-832 (Jan. 15, 1988).
Beckmann, et al., Nucl. Acids Res. vol. 13, No. 14 pp. 5233-5247 (1985).
Sugo et al. Thromb. Hemost. 58(1) 229 1987.
Esmon et al., Develop biol. Standard., 67: 75-82, 1987.
Dreyfus et al., New England Journal of Medicine 325: 1565-1568, 1991.
Taylor et al. J. Clin. Invest. 79: 918-25 1987.
Ikeda et al. Thromb. Res 39: 297-306 1985.
Goding "Monoclonal Antibodies" Academic Press, 1983 pp. 111-113.
Esmon Charles T.
Esmon Naomi L.
Hutzell Paula
Lacey David L.
Oklahoma Medical Research Foundation
LandOfFree
Monoclonal antibody specific for protein C and antibody purifica does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibody specific for protein C and antibody purifica, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibody specific for protein C and antibody purifica will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1154863